Notice2024-11216
Vaccines and Related Biological Products Advisory Committee; Amendment of Notice-Selection of the 2024 to 2025 Formula for COVID-19 Vaccines
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 22, 2024
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Vaccines and Related Biological Products Advisory Committee. This meeting was announced in the Federal Register of March 4, 2024. The amendment is being made to reflect a change in the meeting date in the SUMMARY and DATES portions of the document from May 16, 2024, to June 5, 2024. There are no other changes.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 100 (Wednesday, May 22, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 100 (Wednesday, May 22, 2024)]
[Notices]
[Pages 44996-44997]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-11216]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-0970]
Vaccines and Related Biological Products Advisory Committee;
Amendment of Notice--Selection of the 2024 to 2025 Formula for COVID-19
Vaccines
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of meeting of the Vaccines and Related
Biological Products Advisory Committee. This meeting was announced in
the Federal Register of March 4, 2024. The amendment is being made to
reflect a change in the meeting date in the SUMMARY and DATES portions
of the document from May 16, 2024, to June 5, 2024. There are no other
changes.
FOR FURTHER INFORMATION CONTACT: Kathleen Hayes or Prabhakara Atreya,
Center for Biologics Evaluation and
[[Page 44997]]
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Silver Spring, MD 20993-0002, 301-796-6985, <a href="/cdn-cgi/l/email-protection#d29190978084809082939192b4b6b3fcbabaa1fcb5bda4"><span class="__cf_email__" data-cfemail="064544435450544456474546606267286e6e7528616970">[email protected]</span></a>;
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area). Please call the Information Line for
up-to-date information on this meeting. For press inquiries, please
contact the Office of Media Affairs at 301-796-4540 or
<a href="/cdn-cgi/l/email-protection#335557525c5e52735557521d5b5b401d545c45"><span class="__cf_email__" data-cfemail="711715101e1c10311715105f1919025f161e07">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of March 4, 2024 (89
FR 15590), FDA announced that a meeting of the Vaccines and Related
Biological Products Advisory Committee would be held on May 16, 2024.
On page 15590, in the second column, the SUMMARY and DATES portions of
the document are changed to read as follows:
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Vaccines and Related
Biological Products Advisory Committee (the Committee). The general
function of the Committee is to provide advice and recommendations to
FDA on regulatory issues. On June 5, 2024, the Committee will meet in
open session to discuss and make recommendations on the selection of
the 2024 to 2025 formula for COVID-19 vaccines. The meeting will be
open to the public.
DATES: The meeting will be held virtually on June 5, 2024, from 8:30
a.m. to 4:30 p.m. EST. This notice is issued under the Federal Advisory
Committee Act 5 U.S.C. 1001 et seq. and 21 CFR part 14, relating to the
advisory committees.
Dated: May 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-11216 Filed 5-21-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 22, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.